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Scale (MARS-5), valid and reliable instruments, amongst other questions. The
TSQM yields scores on effectiveness, side-effects, convenience, and global satis-
faction domains. Non-adherence was defined as a score of24 and adherence as a
score of 25 on MARS-5. Multivariate logistic regression and multivariable linear
regression were performed to identify patient characteristics (age, gender, number
of medications, severity, and hypertension drug class) and self-reported reasons
associated with non-adherence and treatment satisfaction.RESULTS:Between No-
vember 2011 and June 2012, 556 MediGuard.org members completed a survey re-
lated to an ACE or ARB: ACE358 (64.4%), ARB198 (35.6%). Patients had mean age
of 62.4 (SD:10.5) years (ACE61.7 years, ARB63.6 years) and 56.3% were female
(ACE58.1%, ARB53.1%). Overall, 51.5% reported medication non-adherence. The
mean TSQM score on effectiveness was 70.4(19.3), side-effects was 95.6(13.8), con-
venience was 84.6(14.0), and global satisfaction was 67.4(19.2). Forgetting, don’t like
to take pills/give injection, and gender were significantly associated with non-
adherence (p0.05). Age, gender, and don’t like to take pills/give injection were
significantly associated with effectiveness, side-effects, and convenience domain
(p0.05), respectively. Age and don’t like to take pills/give injection were signifi-
cantly associated with global satisfaction (p0.05). CONCLUSIONS: In addition to
patient characteristics, patient preferences are important to potentially improve
adherence and satisfaction to hypertension medications.
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OBJECTIVES: To identify multi-attribute utility (MAU) values associated with ve-
nous thromboembolism (VTE) events and to select values for use in economic
models. METHODS: A systematic review of the literature was conducted including
database searches and hand-searching of relevant studies. The database search
included utility studies or RCTs reporting utility scores. The disease area and pop-
ulation were restricted to VTE and adults, respectively. All identified economic
evaluations were hand-searched in order to explore utilities from different eco-
nomic evaluations. Utility sources from three previously developed economic
models for rivaroxaban were also explored. Studies reporting the 8 SF-36 compo-
nents were transformed to EQ-5D using a mapping model outlined by Ara and
Brazier (2008). RESULTS: The database search identified 576 citations, of which 20
studies were included in the review. The hand-search identified 1 study. Two ad-
ditional studies were identified from the economic models, giving a total of 23
studies. Of the 23 studies, 2 studies reported MAUs; 7 studies used direct preference
based measures such as the time trade off technique and the remaining 14 studies
used non-preference based measures such as SF-36. Of the 14 non-preference
based measures, 5 reported mean SF-36 scores for all components and were trans-
formed to EQ-5D. A total of 50 utility values were extracted from the studies. The
selection process identified the following utility scores: 0.62 for DVT, 0.63 for PE and
0.7855 for VTE long-term complications. CONCLUSIONS: There was a large varia-
tion in the extracted utilities (0.04-0.992). Long-term disutility has greater influence
than acute. Cost-utility analyses should model the relationship between acute VTE
events and long-term disutility to capture all health related quality of life impair-
ment.
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OBJECTIVES: To solve problems with recall and aggregation bias in the measure-
ment of utilities it was suggested to determine experienced health moment-by-
moment using the Experience Sampling Method (ESM). This study describes a first
test of feasibility and validity. METHODS: In total 160 persons were included (4
groups with N40; tinnitus, anxiety/depression, atherosclerosis, general public).
ESM data (including health, mood and contextual factors) were collected electron-
ically for six days using a beep questionnaire (10 random times a day) and an
end-of-day questionnaire. In the beep questionnaire a beep-VAS, anchored as the
EQ-5D VAS, was included. In the end-of-day questionnaire the EQ-5D items were
also included, and used to calculate EoD-Utility. Directly before and after the ESM-
period the EQ-5D and Hospital Anxiety and Depression Scale (HADS) were admin-
istered, and used to calculate Before and After utility and VAS scores. Feasibility,
subjective data and convergent validity of ESM, and differences between scores
were analyzed. The relation between beep-VAS, health and mood at beep level
were determined with multilevel analyses. RESULTS: All participants completed
the ESM period and before and after questionnaires. Correlation between beep data
(mean per day) and EoD reports are high for well-being (r.836) and feeling sick
(r.737). Correlations between beep anxiety/depression and the HADS scores are
high (r.627;r.565). In the tinnitus and general public groups, the aggregated
beep-VAS scores (0.65;0.82) are lower than the Before-VAS scores (0.68;0.89) and
After-VAS scores (0.71;0.91). The aggregated EoD-Utility scores (0.80;0.95) are not
different from the After-Utility scores (0.79;0.96). However, in the tinnitus group the
EoD-utility score (0.80) is higher than the Before-Utility score (0.74). Results of the
other groups, and multilevel analyses will be presented at the conference.
CONCLUSIONS: Feasibility and validity of ESM were satisfactory. Health state
scores obtained moment-by-moment using ESM differ from the scores obtained by
using the traditional approach.
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OBJECTIVES: To develop a conceptual model that captures the types of burden and
associated impacts experienced by chronic heart failure (CHF) caregivers.
METHODS: Qualitative interviews were conducted with 24 adult CHF caregivers
from 2 US cities. The 60-minute interviews involved exploratory questions about
the CHF caregiving experience and its impact on caregivers’ quality of life. Data
were analyzed based on Grounded Theory methods. RESULTS: Caregivers were
5311 years, 67% female, 33% non-Caucasian, 37% children of the CHF patients,
17% patient’s spouse and 63% resided with the CHF patient. Qualitative analysis
indicated 4 domains of caregiver burden: (1) physical burdens included tiredness,
health deterioration, physical effort, lack of sleep; (2) emotional/psychological burdens
included feeling overly depended on, worried, guilty, mentally drained, stressed, a
loss of independence, sadness, and feeling overwhelmed; (3) social burdens included
spending less time with family and friends and the decline in the quality of those
relationships, as well as impact on sexual relationships, (4) impact on caregivers’
lifestyles included a lack of time for themselves and non-caregiving tasks, changing
plans, having to stay near to the patient, and the impact at work and on the care-
giver-patient relationship. Many external factors were also described by the care-
givers as impacting the level of burden, such as the patient’s health status or mood,
the volume of the caregivers’ tasks and the level of support from others. This data
has been captured in a conceptual model of CHF caregiver burden. CONCLUSIONS:
The burdens placed on CHF caregivers are multifaceted. The understanding of
these burdens within a valid conceptual model will allow the development of in-
struments to measure the level of CHF caregiver burden. Further research is re-
quired to understand and quantify the link between CHF patients’ symptomology
and the level of burden that this places on caregivers.
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OBJECTIVES: To assess the impact of symptoms in patients with Atrial Fibrilation
(AF) through AF-QoL, a specific questionnaire to measure Health Related Quality of
Life (HRQoL). METHODS: Observational cross-sectional study in cardiologist set-
ting. Patients included were18 years old with paroxystic AF (AFPar) or persistent
AF (AFPer). Main clinical variables: type of AF, NYHA functional stage, symptoms
frequency and duration and CHADS2 index. AF-QoL has 18 items and 3 domains:
psychological, physical and sexual activity, and scores standardized between 0
(worst HRQoL) and 100 (best HRQoL). RESULTS: A total of 824 patients were in-
cluded: 513 (62.3%) with AFPar and 311 (37.7%) with AFPer. 56.1% were male and
mean (SD) age was 68.2 (11.3) years. Patients with AFPar were younger than AFPer
(p0.001). 82.8% and 26.1% of patients with AFPar had palpitations and dyspnea vs.
62.4% and 44.7% of AFPer (p0.001). AFPar was associated to higher thromboem-
bolism risk by CHADS2 (p0.001). Global mean (SD) score for AF-QoL was similar
between both types of AF: 51.23 (23.76) in AFPar and 46.68 (24.48) in AFPer, but
differences were observed in physical domain having AFPar a higher mean score
that AFPer (p0.003). Multivariate analysis showed that being male, having pres-
ence of mild or no symptoms, practicing exercise, having NYHA stage I and II and
not having emergency visits was related with higher score of HRQoL (R20.32;
p0.0001). CONCLUSIONS: AF symptoms have a high impact in HRQoL of patient.
Therapies able to reduce severity of symptoms and number of emergency visits
will have a positive impact on HRQoL in patients with AF.
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OBJECTIVES: The Cambridge Pulmonary Hypertension Outcome Review (CAM-
PHOR) and the Medical Outcomes Study Short Form 36 (SF-36) are widely used to
assess outcome in pulmonary hypertension (PH) patients. The CAMPHOR is a PH-
specific measure consisting of three scales; symptoms, activity limitations and
needs-based QoL. The SF-36 is a generic health status questionnaire consisting of
36 items and eight domains. The aim of this study was to compare the psychomet-
ric properties of these two measures in a population with PH. METHODS: Partici-
pants were recruited from six specialist PH centres in Australia and New Zealand.
They completed the CAMPHOR and SF-36 at two time points, two weeks apart. The
questionnaires were assessed for distributional properties (% scoring minimum
and % scoring maximum), internal consistency (Cronbach’s alpha), test-retest re-
liability (minimum required correlation coefficient  0.85) and construct validity
(CAMPHOR scores by WHO functional classification). RESULTS: The sample com-
prised 65 participants (mean (SD): age 57.2 (14.5) years; male n (%): 14 (21.5)). Most
of the participants were in WHO functional class II (27.7%) or III (61.5%). A high
proportion of participants recorded the maximum score for the SF-36 social func-
tioning (21.3%) and role emotional (25.0%) domains, signifying insensitivity. Test-
retest reliability was below the required level for six of the eight SF-36 domains,
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indicating high levels of random measurement error. Three of the SF-36 domains
did not distinguish between WHO functional classes. Only two of the SF-36 do-
mains (role physical and general health perceptions) met the full psychometric
criteria of the study. In contrast, all CAMPHOR scales exhibited good test retest
reliability and distinguished significantly between WHO functional classes.
CONCLUSIONS:The CAMPHOR has superior psychometric properties, compared to
the SF-36, in the assessment of QoL in individuals with PH.
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OBJECTIVES: To assess the use of quality of life questionnaires in polish cardiac
patients, as well as research methods used by polish authors in terms of interna-
tional quality of life research guidelines. METHODS: Systematic literature review
was performed in order to collect publications assessing quality of life in cardiac
patients in Poland. Medical databases and the most important health agencies
websites were searched for HRQoL assessment guidelines. Inclusion criteria: stud-
ies carried in the Republic of Poland; studies in which authors were using HRQoL
questionnaires in cardiac patients. Exclusion criteria: Studies carried outside of
Poland; studies estimating HRQoL among patients with vascular diseases; case
reports; researches and review papers without HRQoL assessment. Based on the
international guidelines, “checklist” consisting of 19 statements and questions was
created as a basis for data extraction from accessed publications. RESULTS: As a
result of systematic literature review and inclusion criteria application, 131 polish
publications were included in this analysis. 26% of all researches were based on
questionnaires designed by the authors for their own needs, of which 71% have
never been validated. Results of questionnaires were calculated using official key
only in 43% of publications. Among the included studies, 63% assessed HRQoL as a
primary endpoint. Observational studies assessing HRQoL in polish cardiac pa-
tients without any interventions were the most common (41%). At the same time,
36% of studies were related to surgical intervention. CONCLUSIONS: Polish studies
assessing HRQoL in cardiac patients often do not meet all the requirements stated
in international guidelines. Promoting of the results of this work can increase the
awareness of polish authors in terms of proper HRQoL measures.
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OBJECTIVES: To assess the health-related quality of life (HrQoL) in patients with
atrial fibrillation (AF) in Germany and to identify the influence of the associated
AF-specific symptoms on HrQoL. METHODS: HrQoL of AF patients recruited into a
prospective cohort study was assessed by using the written version of the SF 36.
General HrQoL as well as physical and mental component summary scores were
calculated for each patient. Secondly, AF-related symptoms based on the EHRA AF
symptoms classification (palpitations, fatigue, dizziness, dyspnea, chest pain, anx-
iety) were collected by asking each patient to fill out written questionnaires during
visiting a GP. To identify the influence of these symptoms on HrQoL, a linear re-
gression was conducted for each component summary score, while controlling for
additional socio-demographic/AF-related clinical parameters. RESULTS: A total of
526 AF-patients were recruited in 71 study centers (female patients: 45.1 %, average
age: 73.2 years, average CHA2DS2-VASc score: 3.8). The average SF-36-physical
summary score was 38.6 (SD: 10.4). The average SF-36 mental component score was
46.5 (SD: 11.8). Only 14.8 % of the patients reported none of the EHRA-symptoms.
The most frequent symptom was fatigue (72.1 % of all patients). The results of the
first multivariate regression (R20.349) showed that the most important factors
explaining the SF-36-physical component score were fatigue, chest pain, dizziness
and dyspnea. Only two of the control variables had a significant influence on phys-
ical HrQoL (age; number of medications taken). In the second estimate addressing
mental HrQoL (R20.349), none of these factors was significant. The most impor-
tant factors explaining mental HrQoL were palpitations, dizziness and anxiety.
CONCLUSIONS: AF patients in real life care have a limited physical/mental HrQoL.
AF-related symptoms significantly explain the level of HrQoL. Consequently, in
order to increase/maintain the HrQoL of AF patients, it is important to control/
improve scores measured for AF-related symptoms.
PCV95
THE PATIENT’S EXPERIENCE OF NUISANCE BLEEDING AND BRUISING WHILE
ON ANTIPLATELET MEDICATIONS FOR ACS
Gwaltney C1, Slagle A2, Martin ML3, Mollon P4
1Invivodata, Inc., Westerly, RI, USA, 2FDA/CDER/OND, Silver Spring, MD, USA, 3Health
Research Associates, Inc., Seattle, WA, USA, 4Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: Bleeding is a common experience for acute coronary syndrome (ACS)
patients who receive anti-platelet medications. “Nuisance” bleeding and bruising –
non-life threatening events that occur in the patients’ everyday lives and may
impact medication adherence – is not often assessed in clinical trials and existing
measures may not capture all relevant aspects. In this study, we used qualitative
interviews to better understand how patients experience nuisance bleeding and
bruising and its impact. METHODS: One-hour interviews were conducted using a
semi-structured interview guide with patients who had experienced ACS in the
past year. All participants were taking clopidogrel at the time of enrollment into the
study and reported experiencing nuisance bleeding and bruising. Most patients
were male (70%) and white (80%) and the average age was 63.5 years old. Interview
responses were coded using ATLAS.ti software. Data were analyzed by extracting
relevant themes emerging from the interviews and by calculating the percent of
patients expressing a specific concept related to nuisance bleeding and bruising.
RESULTS: Prominent features included the amount of bleeding, difficulty stopping
the bleeding, and the size and color of bruises. Frequency was an important issue
for patients; approximately one-third of patients reported experiencing nuisance
bleeding daily. Patients most often reported that bleeding events lasted only min-
utes, but that bruises often did not heal for weeks. Nuisance bleeding and bruising
appeared to have a significant negative impact on the patients’ daily lives, as it
resulted in behavior changes to avoid bleeding and bruising events and a variety of
negative emotions (e.g., embarrassment, frustration, fear). CONCLUSIONS: Nui-
sance bleeding and bruising can have a significant impact on the lives of ACS
patients on anti-platelet medications. The data from this qualitative interview
study may allow for improved measures of nuisance bleeding and bruising that can
be administered in studies examining antithrombotic therapies.
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OBJECTIVES: Patients with cardiovascular disease (CVD) experience a number of
symptoms, such as tiredness, that can limit their physical activities and disrupt
daily life. Increased inflammation may independently contribute to the experience
of these symptoms and functional limitations, in addition to increasing the risk of
CVD and acute events. The goal of this study was to perform a qualitative review of
published studies that address the link between inflammation and patient func-
tioning among patients with cardiovascular disease. METHODS: Articles were
identified through MEDLINE and PubMed. Search terms included “inflammation,
inflammatory markers, CRP, TNF-, and interleukins” crossed with “fatigue, de-
pression, physical activity, sleep, function, and cardiovascular.” The search re-
turned 938 articles, a total of 112 abstracts were reviewed, and 46 full articles were
examined. Of these, 8 addressed patients with chronic or acute cardiovascular
disease and were included in the review. RESULTS: The articles examined multiple
inflammatory markers, including IL-1, IL-6, TNF-, CRP, IL-10, IL-8, neopterin,
sICAM-1, and IL-1ra. Symptoms and functional limitations measured included fa-
tigue/tiredness, irritability, depression, demoralization, and physical activity/exer-
cise. Significant associations were observed in all 8 studies. The relationship be-
tween inflammation, IL-6 in particular, and tiredness was consistently seen.
Evidence also supported a relationship with depressed mood, but the association
was not uniform across inflammatory markers. Inflammation was also associated
with physical activity, with one study showing that exercise reduced hsCRP and
inflammatory cytokines. CONCLUSIONS: Symptoms and limitations on physical
functioning can substantially burden patients with CVD. Although additional re-
search is needed, this review suggests that inflammatory processes may indepen-
dently contribute to this patient burden. Reducing inflammation may not only
reduce the risk of CVD and associated events, but also directly improve symptoms
and improve functioning. It will be useful to include outcomes assessing these
concepts in trials examining anti-inflammatory treatments in CVD patients.
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OBJECTIVES: To assess the prevalence and impact of dyspepsia among Japanese
Atrial Fibrillation (AF) patients.METHODS: The 2008, 2009, and 2010 Japan National
Health and Wellness Survey (NHWS) datasets were used in this study. The NHWS
is an Internet-based survey administered to the adult population in Japan using a
random stratified sampling framework to ensure demographic representativeness.
Among patients who reported a diagnosis of AF (N565), those with comorbid
dyspepsia were compared with those without dyspepsia on demographics and
health history. These groups were also compared on health status (using the SF-
12v2), work productivity (using the WPAI), and health care resource use (physician
visits, emergency room [ER] visits, and hospitalizations) in the past six months
using multivariate regression modeling and controlling for baseline differences.
RESULTS: Dyspepsia was the most common non cardiovascular comorbidity, af-
fecting over a third (37.4%) of AF patients. This prevalence was higher than in
general population (21.3%). Its presence was not associated with any demographic
or general health history variables. However, patients with dyspepsia used more
AF medications (2.05 vs. 1.54) and had been diagnosed more recently (9.97 vs. 10.58
years). Adjusting for these differences, patients with dyspepsia reported signifi-
cantly worse physical health status (PCS scores: 41.32 vs. 45.66) and health utilities
(0.70 vs. 0.76) (all p0.05). Those patients also reported significantly more overall
work impairment (29.65% vs. 17.02%) and more physician visits (19.35 vs. 12.62),
and ER visits (0.40 vs. 0.14) in the past six months (all p.05). CONCLUSIONS:
Dyspepsia is common among Japanese AF patients. Even after adjusting for con-
founding variables, dyspepsia was significantly associated with poorer health sta-
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